A detailed history of New Edge Advisors, LLC transactions in Amgen Inc stock. As of the latest transaction made, New Edge Advisors, LLC holds 65,313 shares of AMGN stock, worth $17.2 Million. This represents 0.14% of its overall portfolio holdings.

Number of Shares
65,313
Previous 63,809 2.36%
Holding current value
$17.2 Million
Previous $19.9 Million 5.55%
% of portfolio
0.14%
Previous 0.15%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$309.38 - $337.38 $465,307 - $507,419
1,504 Added 2.36%
65,313 $21 Million
Q2 2024

Aug 15, 2024

BUY
$262.75 - $319.31 $3.56 Million - $4.32 Million
13,542 Added 26.94%
63,809 $19.9 Million
Q1 2024

May 14, 2024

SELL
$268.87 - $324.56 $52,429 - $63,289
-195 Reduced 0.39%
50,267 $14.3 Million
Q4 2023

Feb 13, 2024

BUY
$255.7 - $288.46 $1.78 Million - $2.01 Million
6,980 Added 16.05%
50,462 $14.5 Million
Q3 2023

Nov 14, 2023

SELL
$218.65 - $271.46 $804,850 - $999,244
-3,681 Reduced 7.8%
43,482 $11.7 Million
Q2 2023

Aug 14, 2023

BUY
$214.27 - $253.37 $833,081 - $985,102
3,888 Added 8.98%
47,163 $10.5 Million
Q1 2023

May 12, 2023

SELL
$225.79 - $275.2 $464,450 - $566,086
-2,057 Reduced 4.54%
43,275 $10.5 Million
Q4 2022

Feb 14, 2023

BUY
$229.03 - $291.01 $3.16 Million - $4.01 Million
13,776 Added 43.66%
45,332 $11.9 Million
Q3 2022

Nov 14, 2022

BUY
$224.46 - $253.15 $1.1 Million - $1.24 Million
4,893 Added 18.35%
31,556 $7.11 Million
Q2 2022

Aug 09, 2022

SELL
$230.71 - $256.74 $319,071 - $355,071
-1,383 Reduced 4.93%
26,663 $6.49 Million
Q1 2022

May 13, 2022

SELL
$219.27 - $242.57 $85,296 - $94,359
-389 Reduced 1.37%
28,046 $6.78 Million
Q4 2021

Feb 17, 2022

BUY
$198.88 - $227.6 $3.16 Million - $3.61 Million
15,865 Added 126.21%
28,435 $6.4 Million
Q3 2021

Oct 29, 2021

SELL
$212.27 - $248.7 $375,505 - $439,950
-1,769 Reduced 12.34%
12,570 $2.67 Million
Q2 2021

Jul 22, 2021

SELL
$233.58 - $259.14 $779,923 - $865,268
-3,339 Reduced 18.89%
14,339 $3.5 Million
Q1 2021

Apr 26, 2021

SELL
$221.91 - $258.6 $816,406 - $951,389
-3,679 Reduced 17.23%
17,678 $4.4 Million
Q4 2020

Jan 27, 2021

SELL
$216.38 - $257.67 $2.55 Million - $3.03 Million
-11,770 Reduced 35.53%
21,357 $4.91 Million
Q3 2020

Nov 03, 2020

BUY
$234.65 - $260.95 $2.11 Million - $2.35 Million
8,998 Added 37.29%
33,127 $8.42 Million
Q2 2020

Jul 29, 2020

BUY
$197.81 - $242.74 $279,505 - $342,991
1,413 Added 6.22%
24,129 $5.69 Million
Q1 2020

May 04, 2020

BUY
$182.24 - $241.7 $994,665 - $1.32 Million
5,458 Added 31.63%
22,716 $4.61 Million
Q4 2019

Jan 31, 2020

BUY
$189.21 - $243.2 $1.09 Million - $1.4 Million
5,740 Added 49.84%
17,258 $4.16 Million
Q3 2019

Nov 06, 2019

BUY
$174.11 - $208.62 $353,791 - $423,915
2,032 Added 21.42%
11,518 $2.24 Million
Q2 2019

Aug 05, 2019

SELL
$166.7 - $195.41 $9.15 Million - $10.7 Million
-54,868 Reduced 85.26%
9,486 $1.75 Million
Q1 2019

May 09, 2019

BUY
$180.87 - $203.88 $2.53 Million - $2.85 Million
13,978 Added 27.75%
64,354 $573,000
Q4 2018

Jan 29, 2019

BUY
$178.4 - $208.25 $8.02 Million - $9.36 Million
44,946 Added 827.73%
50,376 $9.81 Million
Q3 2018

Oct 29, 2018

SELL
$185.29 - $208.89 $47,063 - $53,058
-254 Reduced 4.47%
5,430 $1.13 Million
Q2 2018

Jul 19, 2018

SELL
$166.05 - $186.51 $109,094 - $122,537
-657 Reduced 10.36%
5,684 $1.05 Million
Q1 2018

May 11, 2018

SELL
$169.43 - $198.0 $821,227 - $959,706
-4,847 Reduced 43.32%
6,341 $1.05 Million
Q4 2017

Feb 08, 2018

SELL
$168.79 - $188.59 $156,805 - $175,200
-929 Reduced 7.67%
11,188 $2.02 Million
Q3 2017

Nov 13, 2017

BUY
$167.29 - $191.0 $218,982 - $250,019
1,309 Added 12.11%
12,117 $2.25 Million
Q2 2017

Aug 16, 2017

BUY
N/A
10,808
10,808 $0

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $141B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track New Edge Advisors, LLC Portfolio

Follow New Edge Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New Edge Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on New Edge Advisors, LLC with notifications on news.